Kawin Technology(SH:688687) Zheng Quan Ri Bao Wang·2025-04-29 02:21Core Insights - The company reported a total revenue of 1.23 billion and a net profit of 142 million for the year 2024, showing a year-on-year growth of 22.18% [1] - In Q1 2025, the company achieved a revenue of 232 million, with a year-on-year increase of 8.90%, and a net profit of 25.67 million, reflecting a growth of 15.92% [1] - The company demonstrated strong resilience in a challenging industry environment [1] Product Development - The company is the first in China to successfully develop a high-cure-rate pan-genotype all-oral series of drugs for hepatitis C, with its core product, the sodium colopavine capsule series, continuing to release strong clinical value [1] - The sodium colopavine capsule successfully renewed its inclusion in the medical insurance catalog in 2024, solidifying its market position and laying a strong foundation for future business expansion [1] Market Strategy - The company has implemented innovative market strategies to address patient access issues in grassroots markets, including deep academic collaborations with liver disease experts and further penetration into county-level markets [1] - The company’s mature products, particularly the interferon series, continue to maintain market leadership, with significant evidence supporting their clinical value [2] - The company’s products, Jinshuxi and Kaiyin Yisheng, have been included in the inter-provincial collection alliance for interferon in 29 provinces, marking a new breakthrough in the centralized procurement field [2] Future Outlook - The company plans to focus on expanding the hepatitis C innovative drug market while deepening its advantageous strategies and promoting county-level marketing [2] - The company aims to enhance the sales scale of mature products through CSO cooperation and brand expansion, continuously optimizing operational performance to create value for shareholders [2]